Agreed 100% that the uplist will be a bullish event in itself. I do not foresee us needing a RS. ONCS is different than other biotechs because we are working towards turning non-responders of the best in class immunotherapy drug of a multibillion $ cancer immunotherapy market to responders and making it THE ultimate solid cancer treatment drug. If P2B preliminary data is good, then as Punit has mentioned before, I foresee a smooth organic uplist.
Market Data 
Markets 
AI
